Stockreport

Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases

Coya Therapeutics, Inc.  (COYA) 
PDF Preclinical study anticipated to be published in 1H 2025 documenting combination’s additive and/or synergistic anti-inflammatory signal;Company will seek to advance asse [Read more]